Phillip Md Et Al Frost Purchases 50,000 Shares of Opko Health Inc. (NASDAQ:OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 50,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were acquired at an average cost of $2.12 per share, for a total transaction of $106,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $6,506,176.12. The purchase was disclosed in a filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, July 12th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.16 per share, for a total transaction of $108,000.00.
  • On Monday, July 8th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.23 per share, for a total transaction of $223,000.00.
  • On Tuesday, July 2nd, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $121,000.00.
  • On Tuesday, June 25th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.01 per share, for a total transaction of $201,000.00.
  • On Thursday, June 20th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.04 per share, for a total transaction of $102,000.00.
  • On Tuesday, June 18th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $2.02 per share, for a total transaction of $101,000.00.
  • On Thursday, June 13th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.92 per share, for a total transaction of $96,000.00.
  • On Tuesday, June 11th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.87 per share, for a total transaction of $93,500.00.
  • On Friday, June 7th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.87 per share, for a total transaction of $93,500.00.
  • On Wednesday, June 5th, Phillip Md Et Al Frost purchased 150,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.92 per share, for a total transaction of $288,000.00.

Shares of OPK stock opened at $2.08 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10. The firm has a 50-day moving average price of $2.08. The company has a market cap of $1.30 billion, a PE ratio of -8.32 and a beta of 2.14. Opko Health Inc. has a 52-week low of $1.73 and a 52-week high of $6.16.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.08). The firm had revenue of $222.50 million during the quarter, compared to the consensus estimate of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The firm’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) earnings per share. As a group, research analysts anticipate that Opko Health Inc. will post -0.42 EPS for the current fiscal year.

OPK has been the topic of several analyst reports. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research cut shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Opko Health currently has a consensus rating of “Buy” and an average target price of $9.25.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Opko Health by 1.4% in the 4th quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock valued at $91,133,000 after purchasing an additional 408,951 shares during the period. Geode Capital Management LLC grew its stake in Opko Health by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 4,078,397 shares of the biotechnology company’s stock valued at $12,275,000 after buying an additional 165,517 shares during the last quarter. Norges Bank acquired a new position in Opko Health in the 4th quarter valued at about $9,207,000. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management grew its stake in Opko Health by 98.4% in the 2nd quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 2,092,606 shares of the biotechnology company’s stock valued at $5,106,000 after buying an additional 1,037,669 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Opko Health by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,661,535 shares of the biotechnology company’s stock worth $5,001,000 after purchasing an additional 10,880 shares in the last quarter. 25.35% of the stock is currently owned by institutional investors.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: QQQ ETF

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.